Background: While approval of CDK 4/6 inhibitors (CDK 4/6i), palbociclib and ribociclib, has changed the landscape of metastatic HR+/HER2– breast cancer, limited population-based data are available regarding therapy utilization for mBC patients after progression on CDK 4/6i. This evidence concerns the gene ERBB2 and breast cancer.